The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Peak Expiratory Flow Rate

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Peak Expiratory Flow Rate


High impact information on Peak Expiratory Flow Rate

  • MAIN OUTCOME MEASURES--Decline in lung function (FEV1), change in bronchial hyperresponsiveness, indicated by a provocative concentration of histamine causing a 20% fall in FEV1 (PC20), morning peak expiratory flow rate (PEFR), diurnal PEFR, week-to-week variation of PEFR, bronchial symptoms, and exacerbations [5].
  • Ten of 17 patients had better control during cloprednol therapy than during previous prednisone regimens, and significant improvement was noted in peak expiratory flow rate during the study period (P less than .001) [6].
  • Histamine challenge in atopic asthmatics at concentrations giving a comparable change in PEFR/FEV1 to that evoked by exercise or inhaled antigen was not associated with the appearance of circulating NCF [7].
  • Patients treated with salmeterol had reduced bronchodilator responses to salbutamol in terms of FEV1 and peak expiratory flow rate (PEFR) than those treated with placebo [8].
  • Cyclosporin therapy resulted in a mean increase above placebo of 12.0% in morning peak expiratory flow rate (PEFR; p less than 0.004) and 17.6% in FEV1 (p less than 0.001) [9].

Chemical compound and disease context of Peak Expiratory Flow Rate


Biological context of Peak Expiratory Flow Rate


Anatomical context of Peak Expiratory Flow Rate


Associations of Peak Expiratory Flow Rate with chemical compounds

  • The reduction in response equated with a 2.5-fold and a fourfold greater dose of salbutamol being required to produce a given FEV1 and PEFR, respectively [8].
  • Salmeterol remained effective in terms of disease control, with a significant improvement in morning PEFR compared with placebo that was maintained over the 4 week treatment period.(ABSTRACT TRUNCATED AT 250 WORDS)[8]
  • 14 asthmatic patients with nocturnal symptoms and morning dips in peak expiratory flow rate (PEFR) were treated with regular inhaled salbutamol for 1 or 2 weeks, followed by regular inhaled beclomethasone dipropionate, in addition to salbutamol, for a further 2 weeks [23].
  • Beclomethasone treatment was associated with improvement in peak expiratory flow rate, alleviation of symptoms, and a decrease in the number of exacerbations in both patient groups [24].
  • Initially, the theophylline group improved significantly more in symptom scores, beta-agonist usage, and peak expiratory flow rate, but at maximal effect there was no significant difference [25].

Gene context of Peak Expiratory Flow Rate

  • Among the patients with emergency asthma flares, those who responded to asthma treatment with an increase in peak expiratory flow rate by an amount equal to at least 20% of their predicted normal value had lower eotaxin levels than those who did not (410 pg/mL [210, 800 pg/mL] and 660 pg/mL [300, 1480 pg/mL], respectively; P =.04) [26].
  • In Group I this was associated with improvements in PEFR, FEV1 and night time wheeze and reduced percentages of CD4/CD25 and CD4/HLA-DR peripheral blood T cells [27].
  • RESULTS: Patients with increased IFN-gamma changes from baseline showed significantly increased changes in morning (P = 0.02) and evening (P < 0.05) PEFR compared with those with decreased IFN-gamma changes [28].
  • Plasma TARC concentration showed inverse correlation with peak expiratory flow rate at presentation [29].
  • We measured daily peak expiratory flow rate (PEFR) and daily respiratory symptoms for 1 yr in 70 COPD patients (52 male, 18 female, mean age [+/- SD] 67.5 +/- 8.3 yr, FEV1 1.06 +/- 0.45 L, FVC 2.48 +/- 0.82 L, FEV1/FVC 44 +/- 15%, FEV1 reversibility 6.7 +/- 9.1%, PaO2 8.8 +/- 1.1 kPa) [30].

Analytical, diagnostic and therapeutic context of Peak Expiratory Flow Rate


  1. Variations in chemical mediators of hypersensitivity in the sputum of chronic bronchitics: correlation with peak expiratory flow. Turnbull, L.W., Turnbull, L.S., Crofton, J., Kay, A.B. Lancet (1978) [Pubmed]
  2. Nifedipine in bronchial asthma. Patakas, D., Vlachoianni, E., Tsara, V., Louridas, G., Argiropoulou, P. J. Allergy Clin. Immunol. (1983) [Pubmed]
  3. Intramuscular triamcinolone acetonide in chronic severe asthma. McLeod, D.T., Capewell, S.J., Law, J., MacLaren, W., Seaton, A. Thorax (1985) [Pubmed]
  4. Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications. Gravenstein, S., Johnston, S.L., Loeschel, E., Webster, A. Drug safety : an international journal of medical toxicology and drug experience. (2001) [Pubmed]
  5. Periodic treatment regimens with inhaled steroids in asthma or chronic obstructive pulmonary disease. Is it possible? van Schayck, C.P., van den Broek, P.J., den Otter, J.J., van Herwaarden, C.L., Molema, J., van Weel, C. JAMA (1995) [Pubmed]
  6. Long-term cloprednol use in chronic asthma. Gavani, U.D., Hyde, J.S., Khurana, S., Manaligod, L.M. JAMA (1979) [Pubmed]
  7. Identification and partial characterization of an exercise-induced neutrophil chemotactic factor in bronchial asthma. Lee, T.H., Nagy, L., Nagakura, T., Walport, M.J., Kay, A.B. J. Clin. Invest. (1982) [Pubmed]
  8. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Grove, A., Lipworth, B.J. Lancet (1995) [Pubmed]
  9. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Alexander, A.G., Barnes, N.C., Kay, A.B. Lancet (1992) [Pubmed]
  10. Exercise-induced urinary excretion of leukotriene E4 in children with atopic asthma. Kikawa, Y., Hosoi, S., Inoue, Y., Saito, M., Nakai, A., Shigematsu, Y., Hirao, T., Sudo, M. Pediatr. Res. (1991) [Pubmed]
  11. Magnesium sulfate for the treatment of bronchospasm complicating acute bronchitis in a four-months'-pregnant woman. Skobeloff, E.M., Kim, D., Spivey, W.H. Annals of emergency medicine. (1993) [Pubmed]
  12. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebuliser therapy. Teale, C., Morrison, J.F., Jones, P.C., Muers, M.F. Respiratory medicine. (1991) [Pubmed]
  13. Effect of intercostal nerve block with 0.5% bupivacaine on peak expiratory flow rate and arterial oxygen saturation in rib fractures. Osinowo, O.A., Zahrani, M., Softah, A. The Journal of trauma. (2004) [Pubmed]
  14. Beta-adrenoceptor blocking effects and plasma levels of bornaprolol and propranolol in man. Thuillez, C., Richer, C., Duhazé, P., Bergougnan, L., Giudicelli, J.F. Eur. J. Clin. Pharmacol. (1985) [Pubmed]
  15. Cutaneous vasoconstrictor response to glucocorticoids in asthma. Brown, P.H., Teelucksingh, S., Matusiewicz, S.P., Greening, A.P., Crompton, G.K., Edwards, C.R. Lancet (1991) [Pubmed]
  16. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. Spector, S.L., Nicodemus, C.F., Corren, J., Schanker, H.M., Rachelefsky, G.S., Katz, R.M., Siegel, S.C. J. Allergy Clin. Immunol. (1995) [Pubmed]
  17. Theophylline kinetics and ventilatory flow in bronchial asthma and chronic airflow obstruction: influence of erythromycin. Richer, C., Mathieu, M., Bah, H., Thuillez, C., Duroux, P., Giudicelli, J.F. Clin. Pharmacol. Ther. (1982) [Pubmed]
  18. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. Holgate, S.T., Arshad, H., Stryszak, P., Harrison, J.E. J. Allergy Clin. Immunol. (2000) [Pubmed]
  19. Diurnal variation and adaptation of the cough response to citric acid in normal subjects. Pounsford, J.C., Saunders, K.B. Thorax (1985) [Pubmed]
  20. Can clinical response to cyclosporin in chronic severe asthma be predicted by an in vitro T-lymphocyte proliferation assay? Alexander, A.G., Barnes, N.C., Kay, A.B., Corrigan, C.J. Eur. Respir. J. (1996) [Pubmed]
  21. Effects of naturally-occurring acid fog on inflammatory mediators in airway and pulmonary functions in asthmatic patients. Honma, S., Tanaka, H., Teramoto, S., Igarashi, T., Abe, S. Respiratory medicine. (2000) [Pubmed]
  22. Adult asthma and gastro-oesophageal reflux: the effects of omeprazole therapy on asthma. Teichtahl, H., Kronborg, I.J., Yeomans, N.D., Robinson, P. Australian and New Zealand journal of medicine. (1996) [Pubmed]
  23. Inhaled therapy reduces morning dips in asthma. Horn, C.R., Clark, T.J., Cochrane, G.M. Lancet (1984) [Pubmed]
  24. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Dompeling, E., van Schayck, C.P., van Grunsven, P.M., van Herwaarden, C.L., Akkermans, R., Molema, J., Folgering, H., van Weel, C. Ann. Intern. Med. (1993) [Pubmed]
  25. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. The Zileuton Study Group. Schwartz, H.J., Petty, T., Dubé, L.M., Swanson, L.J., Lancaster, J.F. Arch. Intern. Med. (1998) [Pubmed]
  26. Elevated plasma eotaxin levels in patients with acute asthma. Lilly, C.M., Woodruff, P.G., Camargo, C.A., Nakamura, H., Drazen, J.M., Nadel, E.S., Hanrahan, J.P. J. Allergy Clin. Immunol. (1999) [Pubmed]
  27. Inhaled glucocorticoid therapy of childhood asthma is associated with reduced peripheral blood T cell activation and 'Th2-type' cytokine mRNA expression. Gemou-Engesaeth, V., Bush, A., Kay, A.B., Hamid, Q., Corrigan, C.J. Pediatrics (1997) [Pubmed]
  28. Relationship between changes in interferon-gamma production by peripheral blood T cells and changes in peak expiratory flow rate in patients with chronic stable asthma. Koh, Y.I., Choi, I.S., Lee, H.C. Clin. Exp. Allergy (2002) [Pubmed]
  29. Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children. Leung, T.F., Wong, C.K., Lam, C.W., Li, A.M., Ip, W.K., Wong, G.W., Fok, T.F. Eur. Respir. J. (2003) [Pubmed]
  30. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Seemungal, T.A., Donaldson, G.C., Paul, E.A., Bestall, J.C., Jeffries, D.J., Wedzicha, J.A. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
  31. The influence of parasympatholytics on the resolution of acute attacks of asthma. McFadden, E.R., elSanadi, N., Strauss, L., Galan, G., Dixon, L., McFadden, C.B., Shoemaker, L., Gilbert, L., Warren, E., Hammonds, T. Am. J. Med. (1997) [Pubmed]
  32. Neutrophil chemotactic activity in milk-induced asthma. Papageorgiou, N., Lee, T.H., Nagakura, T., Cromwell, O., Wraith, D.G., Kay, A.B. J. Allergy Clin. Immunol. (1983) [Pubmed]
  33. Vascular risk factors and cognitive function in a sample of independently living men. Aleman, A., Muller, M., de Haan, E.H., van der Schouw, Y.T. Neurobiol. Aging (2005) [Pubmed]
  34. Serum interleukin 5 concentrations in atopic and non-atopic patients with glucocorticoid-dependent chronic severe asthma. Alexander, A.G., Barkans, J., Moqbel, R., Barnes, N.C., Kay, A.B., Corrigan, C.J. Thorax (1994) [Pubmed]
  35. Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled trial. Ciarallo, L., Sauer, A.H., Shannon, M.W. J. Pediatr. (1996) [Pubmed]
WikiGenes - Universities